Optimization of migraine attacks relief
G. R. Tabeeva,
A. V. Amelin,
L. R. Akhmadeeva,
A. B. Danilov,
O. B. Doronina,
M. I. Koreshkina,
N. V. Latysheva,
E. G. Mendelevich,
I. V. Sarvilina,
A. V. Sergeev,
K. V. Skorobogatykh,
E. G. Filatova https://doi.org/10.14412/2074-2711-2023-2-126-133
Abstract
On December 24, 2022, in Moscow an interdisciplinary Council of Headache Experts, held under the auspice of the interregional public organization “Russian Society for the Study of Headache”, discussed the key problems of effective treatment of a migraine attack and the possibilities of a specific drug Kaporiza® (rizatriptan). Despite the development of strategies for the relief of migraine attacks and the effectiveness of triptans as first-line therapy, the choice of a specific drug in accordance with the individual clinical profile of the patient is difficult due to the existence of drugs in various forms (standard tablets, oral dispersible forms, injections, nasal sprays, rectal suppositories). Rizatriptan in the form of an orally dispersible tablet (ODT) has a number of advantages: high bioavailability, fast onset of action, and ease of use. Therefore, Kaporiza® (rizatriptan ODT) may be recommended as a priority therapy for all migraine patients who prefer the dispersible tablet form and who experience symptoms of nausea and vomiting, as well as for patients who have experience of poor efficacy and/or poor tolerability of other triptans. The Expert Council recommends to include rizatriptan ODT in the next edition of the clinical guidelines for the diagnosis and treatment of migraine as a first-line agent with Level A evidence.
About the Authors
G. R. Tabeeva
I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
Russian Federation
Competing Interests:
Russian Federation
8, Trubetskaya St., Build. 2, Moscow 119991
Competing Interests:
Publication of this article has been supported by Sotex PharmFirma. The article expresses the position of the authors, which may differ from that of Sotex PharmFirma. The authors are solely responsible for submitting the final version of the manuscript for publication. All the authors have participated in developing the concept of the article and in writing the manuscript. The final version of the manuscript has been approved by all the authors.
A. V. Amelin
Acad. I.P. Pavlov First Saint Petersburg State Medical University of Ministry of Health of Russia
Russian Federation
Competing Interests:
Russian Federation
6-8, L’va Tolstogo St., St. Petersburg 197022
Competing Interests:
Publication of this article has been supported by Sotex PharmFirma. The article expresses the position of the authors, which may differ from that of Sotex PharmFirma. The authors are solely responsible for submitting the final version of the manuscript for publication. All the authors have participated in developing the concept of the article and in writing the manuscript. The final version of the manuscript has been approved by all the authors.
L. R. Akhmadeeva
Bashkir State Medical University, Ministry of Health of Russia
Russian Federation
Competing Interests:
Russian Federation
3, Lenina St., Ufa 450008
Competing Interests:
Publication of this article has been supported by Sotex PharmFirma. The article expresses the position of the authors, which may differ from that of Sotex PharmFirma. The authors are solely responsible for submitting the final version of the manuscript for publication. All the authors have participated in developing the concept of the article and in writing the manuscript. The final version of the manuscript has been approved by all the authors.
A. B. Danilov
I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
Russian Federation
Competing Interests:
Russian Federation
8, Trubetskaya St., Build. 2, Moscow 119991
Competing Interests:
Publication of this article has been supported by Sotex PharmFirma. The article expresses the position of the authors, which may differ from that of Sotex PharmFirma. The authors are solely responsible for submitting the final version of the manuscript for publication. All the authors have participated in developing the concept of the article and in writing the manuscript. The final version of the manuscript has been approved by all the authors.
O. B. Doronina
“Neurosciences and Education”;
“Sibneuromed” LLC
Russian Federation
Competing Interests:
Russian Federation
5, Vokzalnaya Magistral St., Novosibirsk 630004
Competing Interests:
Publication of this article has been supported by Sotex PharmFirma. The article expresses the position of the authors, which may differ from that of Sotex PharmFirma. The authors are solely responsible for submitting the final version of the manuscript for publication. All the authors have participated in developing the concept of the article and in writing the manuscript. The final version of the manuscript has been approved by all the authors.
M. I. Koreshkina
“Medical College AdelMed” LLC
Russian Federation
Competing Interests:
Russian Federation
1, Michurinskaya St., Saint Petersburg 197046
Competing Interests:
Publication of this article has been supported by Sotex PharmFirma. The article expresses the position of the authors, which may differ from that of Sotex PharmFirma. The authors are solely responsible for submitting the final version of the manuscript for publication. All the authors have participated in developing the concept of the article and in writing the manuscript. The final version of the manuscript has been approved by all the authors.
N. V. Latysheva
I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia;
Acad. A. Vein Clinic of Headache and Autonomic Disorders
Russian Federation
Competing Interests:
Russian Federation
8, Trubetskaya St., Build. 2, Moscow 119991;
10B, Staropetrovskiy proezd, Moscow 125130
Competing Interests:
Publication of this article has been supported by Sotex PharmFirma. The article expresses the position of the authors, which may differ from that of Sotex PharmFirma. The authors are solely responsible for submitting the final version of the manuscript for publication. All the authors have participated in developing the concept of the article and in writing the manuscript. The final version of the manuscript has been approved by all the authors.
E. G. Mendelevich
Kazan State Medical University, Ministry of Health of Russia
Russian Federation
Competing Interests:
Russian Federation
49, Butlerova St., Kazan 420012
Competing Interests:
Publication of this article has been supported by Sotex PharmFirma. The article expresses the position of the authors, which may differ from that of Sotex PharmFirma. The authors are solely responsible for submitting the final version of the manuscript for publication. All the authors have participated in developing the concept of the article and in writing the manuscript. The final version of the manuscript has been approved by all the authors.
I. V. Sarvilina
Medical Center Novomeditsina LLC
Russian Federation
Competing Interests:
Russian Federation
74, Sotsialisticheskaya St., Rostov-on-Don 344002
Competing Interests:
Publication of this article has been supported by Sotex PharmFirma. The article expresses the position of the authors, which may differ from that of Sotex PharmFirma. The authors are solely responsible for submitting the final version of the manuscript for publication. All the authors have participated in developing the concept of the article and in writing the manuscript. The final version of the manuscript has been approved by all the authors.
A. V. Sergeev
I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia;
“Chaika Clinic” LLC
Russian Federation
Competing Interests:
Russian Federation
8, Trubetskaya St., Build. 2, Moscow 119991;
9, Lesnaya St., Moscow 125196
Competing Interests:
Publication of this article has been supported by Sotex PharmFirma. The article expresses the position of the authors, which may differ from that of Sotex PharmFirma. The authors are solely responsible for submitting the final version of the manuscript for publication. All the authors have participated in developing the concept of the article and in writing the manuscript. The final version of the manuscript has been approved by all the authors.
K. V. Skorobogatykh
University Headache Clinic LLC
Russian Federation
Competing Interests:
Russian Federation
2, Molodogvardeiskaya St., Build. 1, Moscow 121467
Competing Interests:
Publication of this article has been supported by Sotex PharmFirma. The article expresses the position of the authors, which may differ from that of Sotex PharmFirma. The authors are solely responsible for submitting the final version of the manuscript for publication. All the authors have participated in developing the concept of the article and in writing the manuscript. The final version of the manuscript has been approved by all the authors.
E. G. Filatova
I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia;
Acad. A. Vein Clinic of Headache and Autonomic Disorders
Russian Federation
Competing Interests:
Russian Federation
8, Trubetskaya St., Build. 2, Moscow 119991;
10B, Staropetrovskiy proezd, Moscow 125130
Competing Interests:
Publication of this article has been supported by Sotex PharmFirma. The article expresses the position of the authors, which may differ from that of Sotex PharmFirma. The authors are solely responsible for submitting the final version of the manuscript for publication. All the authors have participated in developing the concept of the article and in writing the manuscript. The final version of the manuscript has been approved by all the authors.
References
1. World Health Organization. Atlas of headache disorders and resources in the world 2011. A collaborative project of World Health Organization and Lifting The Burden. 2011. ISBN: 9789241564212
2. GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020 Oct 17;396(10258):1204-22. doi: 10.1016/S0140-6736(20)30925-9
3. Steiner TJ, Stovner LJ, Jensen R, et al; Lifting The Burden: the Global Campaign against Headache. Migraine remains second among the world's causes of disability, and first among young women: findings from GBD2019. J Headache Pain. 2020 Dec 2;21(1):137. doi: 10.1186/s10194-020-01208-0
4. Tabeeva GR. Headaches in general medical practice. Terapevticheskiy arkhiv = Therapeutic archive. 2022;94(1):114-21. doi: 10.26442/00403660.2022.01.201325 (In Russ.).
5. Diener HC, Tassorelli C, Dodick DW, et al. Guidelines of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults: Fourth edition. Cephalalgia. 2019;39(6):687-710. doi: 10.1177/0333102419828967
6. Silberstein SD, Newman LC, Marmura MJ, et al. Efficacy endpoints in migraine clinical trials: the importance of assessing freedom from pain. Curr Med Res Opin. 2013 Jul;29(7):861-7. doi: 10.1185/03007995.2013.787980. Epub 2013 May 22.
7. Food and Drug Administration. Migraine: developing drugs for acute treatment. Guidance for industry. 2018. Available from: https://www.fda.gov/downloads/drugs/guidances/ucm419465.pdf (accessed 18.07.2018).
8. Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: the American Headache Society evidence assessment of migraine pharmacotherapies. Headache. 2015 Jan;55(1):3-20. doi: 10.1111/head.12499
9. Lipton RB, Buse DC, Adams AM, et al. Treatment Patterns and Unmet Needs in the Acute Treatment of Migraine. J Fam Pract. 2020 Jan/Feb;69(1 Suppl):S1-S7.
10. Mayans L, Walling A. Acute migraine headache: treatment strategies. Am Fam Physician. 2018 Feb 15;97(4):243-51.
11. Hutchinson S, Lipton RB, Ailani J, et al. Characterization of Acute Prescription Migraine Medication Use: Results From the CaMEO Study. Mayo Clin Proc. 2020 Apr;95(4):709-18. doi: 10.1016/j.mayocp.2019.11.025
12. Lipton RB, Munjal S, Alam A, et al. Migraine in America Symptoms and Treatment (MAST) Study: Baseline study methods, treatment patterns, and gender differences. Headache. 2018;58(9):1408-26. doi: 10.1111/head.13407
13. Katic BJ, Rajagopalan S, Ho TW, et al. Triptan persistency among newly initiated users in a pharmacy claims database. Cephalalgia. 2011;31(4):488-500. doi: 10.1177/0333102410383058
14. Serrano D, Buse DC, Kori SH, et al. Effects of switching acute treatment on disability in migraine patients using triptans. Headache. 2013;53(9):1415-29. doi: 10.1111/head.12164
15. Lanteri-Minet M, Massiou H, Romatet S, et al. An instrument to assess patient perception of satisfaction with acute migraine treatment (EXPERT Study). Headache. 2011;51:590-601. doi: 10.1111/j.1526-4610.2011.01867.x
16. Bigal ME, Borucho S, Serrano D, et al. The acute treatment of episodic and chronic migraine in the US. Cephalalgia. 2009;29:891-7. doi: 10.1111/j.1468-2982.2008.01819.x
17. Tabeeva GR, Katsarava Z, Amelin AV, et al. New insights into the burden of migraine: a semantic analysis of the voice of Russian patients – Web 2.0 users. Nevrologiya, neyropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2021;13(6):73-84. doi: 10.14412/2074-2711-2021-6-73-84 (In Russ.).
18. Bigal ME, Serrano D, Buse D, et al. Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal populationbased study. Headache. 2008;48(8):1157-68. doi: 10.1111/j.1526-4610.2008.01217.x
19. Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1-211. doi: 10.1177/0333102417738202
20. Ailani J, Burch RC, Robbins MS on behalf of the Board of Directors of the American Headache Society. The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice. Headache. 2021 Jul;61(7):1021-39. doi: 10.1111/head.14153. Epub 2021 Jun 23.
21. Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the quality standards subcommittee of the American academy of neurology. Neurology. 2000;55(6):754-62. doi: 10.1212/wnl.55.6.754
22. Tabeeva GR. Specific treatment of migraine: a history of one triptan. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2007;(5):75-8 (In Russ.).
23. Migraine: developing drugs for acute treatment [Internet]. Food and Drug Administration; 2018. Available from: https://www.fda.gov/regulatoryinformation/search-fdaguidancedocuments/migraine-developingdrugs-acute-treatment (accessed 16.01.2020).
24. Cameron C, Kelly S, Hsieh SC, et al. Triptans in the acute treatment of migraine: A systematic review and network meta-analysis. Headache. 2015;55(Suppl 4):221-35. doi: 10.1111/head.12601
25. Cutrer FM, Goadsby PJ, Ferrari MD, et al. Priorities for triptan treatment attributes and the implications for selecting an oral triptan for acute migraine: a study of US primary care physicians (the TRIPSTAR Project). Clin Ther. 2004 Sep;26(9):1533-45. doi: 10.1016/j.clinthera.2004.09.011
26. Sacco S, Lampl C, Amin FM, et al. European Headache Federation (EHF) consensus on the definition of effective treatment of a migraine attack and of triptan failure. J Headache Pain. 2022 Oct 12;23(1):133. doi: 10.1186/s10194-022-01502-z
27. Oswald JC, Schuster NM. Lasmiditan for the treatment of acute migraine: a review and potential role in clinical practice. J Pain Res. 2018;11:2221-7. doi: 10.2147/JPR.S152216
28. Hepp Z, Dodick DW, Varon SF, et al. Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia. 2015;35(6):478-88. doi: 10.1177/0333102414547138
29. Silberstein SD. Migraine symptoms: results of a survey of self reported migraineurs. Headache. 1995;35:38. doi: 10.1111/j.1526-4610.1995.hed3507387.x
30. Dahlof CGH, Hargreaves RJ. Pathophysiology and pharmacology of migraine: is there a place for antiemetics in future treatment strategies. Cephalalgia. 1998;18:593-604. doi: 10.1046/j.1468-2982.1998.1809593.x
31. Schurks M, Buring JE, Kurth T. Migraine, migraine features, and cardiovascular disease. Headache. 2010;50:1031-40. doi: 10.1111/j.1526-4610.2009.01609.x
32. May A, Schulte LH. Chronic migraine: risk factors, mechanisms and treatment. Nat Rev Neurol. 2016 Aug;12(8):455-64. doi: 10.1038/nrneurol.2016.93
33. Lipton RB, Stewart WF. Acute migraine therapy: do doctors understand what patients with migraine want from therapy? Headache. 1999;39 Suppl.2:20-6. doi: 10.1046/j.1526-4610.2002.0420s1003.x
34. Aurora SK, Papapetropoulos S, Kori SH, et al. Gastric stasis in migraineurs: etiology, characteristics, and clinical and therapeutic implications. Cephalalgia. 2013 Apr;33(6):408-15. doi: 10.1177/0333102412473371
35. Masaoka T, Tack J. Gastroparesis: Current concepts and management. Gut Liver. 2009;3:166-73. doi: 10.5009/gnl.2009.3.3.166
36. Waseem S, Moshiree B, Draganov PV. Gastroparesis: Current diagnostic challenges and management considerations. World J Gastroenterol. 2009;15:25-37. doi: 10.5009/gnl.2009.3.3.166
37. Peroutka SJ. Re: A sympathetic view of “2003 Wolff Award: Possible parasympathetic contributions to peripheral and central sensitization during migraine”. Headache. 2004;44:731-32. doi: 10.1111/j.1526-4610.2004.04134_5.x
38. Rapoport AM, Freitag F, Pearlman SH. Innovative delivery systems for migraine: The clinical utility of a transdermal patch for the acute treatment of migraine. CNS Drugs. 2010;24:929-40. doi: 10.2165/11317540-000000000-00000
39. Volans GN. Absorption of effervescent aspirin during migraine. Br Med J. 1974;4:265-8. doi: 10.1136/bmj.4.5939.265
40. Tokola RA, Neuvonen PJ. Effects of migraine attack and metoclopramide on the absorption of tolfenamic acid. Br J Clin Pharmacol. 1984;17:67-75. doi: 10.1111/j.1365-2125.1984.tb05001.x
41. Aurora S, Kori S, Barrodale P, et al. Gastric stasis occurs in spontaneous, visually induced, and interictal migraine. Headache. 2007;47:1443-6. doi: 10.1111/j.1526-4610.2007.00922.x
42. Thomsen LL, Dixon R, Lassen LH, et al. 311C90 (zolmitriptan), a novel centrally and peripheral acting oral 5-hydroxytryptamine-1D agonist: A comparison of its absorption during a migraine attack and in a migraine-free period. Cephalalgia. 1996;16:270-5. doi: 10.1046/j.1468-2982.1996.1604270.x
43. Krymchantowski AV, Filho PF, Bigal ME. Rizatriptan vs. rizatriptan plus trimebutine for the acute treatment of migraine: A doubleblind, randomized, crossover, placebo-controlled study. Cephalalgia. 2006;26:871-4. doi: 10.1111/j.1468-2982.2006.01136.x
44. Marmura MJ. Use of dopamine antagonists in treatment of migraine. Curr Treat Options Neurol. 2012;14:27-35. doi: 10.1007/s11940-011-0150-9
45. Habib W, Khankari R, Hontz J. Fast-dissolve drug delivery systems. Crit Rev Ther Drug Carrier Syst. 2000;17(1):61-72.
Review
For citations:
Tabeeva GR, Amelin AV, Akhmadeeva LR, Danilov AB, Doronina OB, Koreshkina MI, Latysheva NV, Mendelevich EG, Sarvilina IV, Sergeev AV, Skorobogatykh KV, Filatova EG. Optimization of migraine attacks relief. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2023;15(2):126-133. (In Russ.) https://doi.org/10.14412/2074-2711-2023-2-126-133
Views:
549
Email this article 